Vicore Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://vicorepharma.com
Clinical Trials
24
Active:8
Completed:11
Trial Phases
4 Phases
Phase 1:8
Phase 2:10
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 2
10 (45.5%)Phase 1
8 (36.4%)Not Applicable
2 (9.1%)phase_2_3
1 (4.5%)Phase 3
1 (4.5%)A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Phase 2
Recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 270
- Registration Number
- NCT06588686
- Locations
- 🇺🇸
UAB Hospital, School of Medicine/Lung Health Center, Birmingham, Alabama, United States
🇺🇸Keck Medicine of University of Southern California, Los Angeles, California, United States
🇺🇸Paradigm Clinical Research Centers, Inc., Redding, California, United States
A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 11
- Registration Number
- NCT05831644
- Locations
- 🇸🇪
Skånes universitetssjukhus, Malmö, Sweden
A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers
Phase 1
Completed
- Conditions
- Drug Interaction
- Interventions
- Drug: Drug Drug Interaction
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 19
- Registration Number
- NCT05830799
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
Phase 1
Completed
- Conditions
- ToleranceIdiopathic Pulmonary FibrosisPulmonary HypertensionSafety Issues
- Interventions
- Drug: PlaceboDrug: C106 solution
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 80
- Registration Number
- NCT05427253
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF
Not Applicable
Active, not recruiting
- Conditions
- Pulmonary FibrosisAnxiety
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 108
- Registration Number
- NCT05330312
- Locations
- 🇺🇸
Curebase Study Site, San Francisco, California, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found